Targeting STAT3 pathway signalling in EGFR TKI resistant NSCLC Source: Virtual Congress 2020 – Chronic lung diseases: novel methods, diagnostics and biomarkers Year: 2020
Targeting of STAT3 and survivin with TG101209, a novel JAK2 inhibitor, enhances radiotherapy in lung cancer models Source: Annual Congress 2010 - New insights in the pathology of lung cancer Year: 2010
Synergistic anti-tumor effects of vandetanib, an inhibitor of VEGFR and EGFR tyrosine kinase inhibitor, combined with cytotoxic agents in lung cancer cell lines Source: Annual Congress 2010 - Treatment of lung cancer Year: 2010
p38 MAPK inhibitors in COPD Source: Annual Congress 2012 - Molecular biology of pro- and anti-inflammatory responses in the lung Year: 2012
The effects of oral p38 mitogen activated protein kinase (MAPK) inhibitor SB-681323 on blood biomarkers in COPD Source: Annual Congress 2008 - Novel treatments for respiratory disease Year: 2008
Reduction of drug resistance through calcium control in epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) resistant lung cancer cells Source: Virtual Congress 2020 – Molecular alterations and immunology in lung cancer Year: 2020
Thrombin induces epithelial-mesenchymal transition via PAR1, PKC and ERK1/2 pathways in A549 cells Source: Annual Congress 2012 - Diffuse parenchymal lung disease pathogenesis, biomarkers, therapy and new entities Year: 2012
Constitutive phosphorylation of p38 mitogen activated protein kinase controls proliferation of mesothelioma cells Source: Eur Respir J 2005; 26: Suppl. 49, 225s Year: 2005
Transmission of muscarinic receptor mediated proliferative effects in human lung fibroblasts involves ERK-MAP kinase, but not PI-3 kinase and Rho-kinase pathway Source: Annual Congress 2007 - Miscellaneous pulmonary pharmacology Year: 2007
Insulin-dependent PI3-Kinase/Akt and ERK signaling pathways inhibit TLR3-mediated HBEC apoptosis Source: Annual Congress 2011 - Recent developments in COPD Year: 2011
Inhibition of GM-CSF generation in human alveolar macrophages by reduction of histone acetylation and by dephosphorylation of p38 MAPK and MKK-1 Source: Eur Respir J 2001; 18: Suppl. 33, 475s Year: 2001
RV568, a narrow-spectrum kinase inhibitor with p38 MAPK-a and -? selectivity, suppresses COPD inflammation Source: Eur Respir J, 50 (4) 1700188; 10.1183/13993003.00188-2017 Year: 2017
LSC 2010 Abstract: Mesothelioma cell proliferation is controlled by mitogen activated protein kinase Erk1/2 and p38 and subsequent C/EBP-β activation Source: Annual Congress 2010 - Basic mechanisms in malignant pleural disease biology Year: 2010
Corticosteroids reduce pro-inflammatory cytokine expression in airway smooth muscle cells via upregulation of MAPK phosphatase-1 and inhibition of p38 MAPK signalling Source: Eur Respir J 2005; 26: Suppl. 49, 713s Year: 2005
Effects of glucocorticoids on activation of extracellular signal-regulated kinases (ERK) in human pulmonary endothelial cells Source: Eur Respir J 2001; 18: Suppl. 33, 160s Year: 2001
Modulation of p38 MAPK and NF-κB activation by the anaesthetic agent thiopental (TP) in A549 cells Source: Eur Respir J 2004; 24: Suppl. 48, 100s Year: 2004
Blocking beta adrenergic signaling may be a target for overcoming EGFR TKI resistance. Source: International Congress 2018 – Lung cancer: from the bench to the bedside Year: 2018
LATE-BREAKING ABSTRACT: Evaluation of an oral p38 mitogen activated protein kinase (MAPK inhibitor) SB-681323 in COPD Source: Annual Congress 2009 - COPD: from biomarker profiling to clinical assessment Year: 2009
Pulmonary complications of Bcr-Abl tyrosine kinase inhibitors Source: Eur Respir J, 56 (4) 2000279; 10.1183/13993003.00279-2020 Year: 2020